{"id":3122,"date":"2026-04-05T17:26:27","date_gmt":"2026-04-05T17:26:27","guid":{"rendered":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/?p=3122"},"modified":"2026-04-05T17:26:27","modified_gmt":"2026-04-05T17:26:27","slug":"new-injectable-treatment-shows-promise-for-thyroid-eye-disease-in-major-clinical-trial","status":"publish","type":"post","link":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/new-injectable-treatment-shows-promise-for-thyroid-eye-disease-in-major-clinical-trial\/","title":{"rendered":"New Injectable Treatment Shows Promise for Thyroid Eye Disease in Major Clinical Trial"},"content":{"rendered":"<p>A new medication called elegrobart, developed by Viridian Therapeutics, has shown encouraging results in a large clinical trial for people with active thyroid eye disease, a condition that affects the eyes. In the REVEAL-1 trial, patients received either the medication or a placebo as a subcutaneous (under-the-skin) injection every 4 weeks, every 8 weeks, or not at all. By week 24, a significant number of patients who received the medication saw improvements in eye bulging (proptosis), with 54% of those on the 4-week schedule and 63% of those on the 8-week schedule showing better results. Only 18% of patients in the placebo group saw such improvements. Additionally, more than half of the patients receiving the 4-week dose no longer experienced double vision (diplopia).<\/p>\n<p>Steve Mahoney, CEO of Viridian Therapeutics, expressed excitement about these findings, noting that REVEAL-1 is the largest trial ever conducted for active thyroid eye disease. He highlighted that elegrobart could become the first-ever self-injectable treatment for this condition, given as few as three doses under the skin. Currently, the only approved treatment requires eight intravenous (IV) infusions per year, which can be inconvenient and less accessible for patients.<\/p>\n<p>Dr. Prem Subramanian, an ophthalmology professor at the University of Colorado, praised the results, stating that elegrobart led to rapid and meaningful reductions in eye bulging and double vision, with a dosing schedule that is both convenient and well-tolerated. He emphasized that patients need more options for managing thyroid eye disease and a treatment that is easier to administer.<\/p>\n<p>Viridian Therapeutics also shared that another trial, REVEAL-2, which is testing elegrobart for chronic thyroid eye disease, is progressing as planned. The company expects to release results in the second quarter of 2026 and plans to submit the medication for regulatory approval in the following year.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A new medication called elegrobart, developed by Viridian Therapeutics, has shown encouraging results in a large clinical trial for people [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":3123,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[543],"tags":[],"class_list":["post-3122","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmaceutical-news"],"_links":{"self":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts\/3122","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/comments?post=3122"}],"version-history":[{"count":1,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts\/3122\/revisions"}],"predecessor-version":[{"id":3128,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts\/3122\/revisions\/3128"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/media\/3123"}],"wp:attachment":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/media?parent=3122"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/categories?post=3122"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/tags?post=3122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}